Introduction
Antares Pharmaceuticals (ATRS) is a developer of intramuscular and subcutaneous injection devices including the VIBEX and VIBEXQuickShot pressure-assisted delivery systems. The company possesses several promising candidates in its pipeline; performed an impressive XYOSTED launch in its recent quarters, and is projected to generate over $175 million in new revenues from collaboration efforts with its partners. In context, this is a company with an enterprise value of only $500 million. Without further ado, let's take a look at ATRS' growth potential.
Table of Contents
Recent Catalysts:
Source: Company Q12019 Presentation
XYOSTED is the